CO-DIAGNOSTICS, INC. Form 8-K (Jan. 6, 2021)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated January 6, 2021. Under Item 2.02 the company states that it issued a press release announcing preliminary revenue results for its fourth quarter ended December 31, 2020, attached as Exhibit 99.1. Item 7.01 incorporates the Item 2.02 disclosure by reference. The signature block carries /s/ Dwight H. Egan, Chief Executive Officer (Principal Executive Officer), dated January 6, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM
8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the

Securities
Exchange Act of 1934

Date
of report (Date of earliest event reported): January 6, 2021

CO-DIAGNOSTICS,
 INC.
(Exact
 name of small business issuer as specified in its charter)
Utah | 1-38148 | 46-2609363
(State or other jurisdiction
 of | (Commission | (IRS Employer
incorporation or
 organization) | File Number) | Identification Number)

2401
S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address
of principal executive offices)

(801)
438-1036

(Issuer’s
telephone number)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

[ ] | Written communications
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] | Soliciting material
 pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] | Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] | Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class | Trading
 Symbol(s) | Name
 of each exchange on which registered
Common Stock, par
 value $0.001 per share | CODX | NASDAQ-CM

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company [X]

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item
2.02. Results of Operations and Financial Condition

On
January 6, 2021, Co-Diagnostics, Inc. issued a press release announcing preliminary revenue results for its fourth quarter ended
December 31, 2020. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

The
information in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933,
as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly
set forth by specific reference in such filing.

Item
7.01 Regulation FD Disclosure.

The
disclosure included under Item 2.02 of this Form 8-K is incorporated by reference herein.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits

Exhibit
 No.: | Description:
99.1 | Press Release, dated January 6, 2021

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS, INC.
Date:
 January 6, 2021 | By: | /s/
 Dwight H. Egan
Name: | Dwight H. Egan
Title: | Chief
 Executive Officer (Principal
 Executive Officer)

File and source

File

SEC_CODX_8-K_filed2021-01-06_0001493152-21-000275.htm

Size

29,300 bytes

SHA-256

28e751f56776c4c7cccf9754b646b81b4d4c0b56a4b915503a15a8ba9a55fecc

Our copy

SEC_CODX_8-K_filed2021-01-06_0001493152-21-000275.htm

Original

www.sec.gov